In response to YS administration, we also found an increase in the expression of ceruloplasmin (Cp), a ferroxidase enzyme present in CSF which has a neuroprotective role during cerebral ischemia [31] and displays oxidative deamidation in the CSF of Alzheimer’s and Parkinson’s disease patients [32]. The gene discussed is CP; the disease is Parkinson disease.